Abstract | BACKGROUND: METHODS: RESULTS: Three hundred and nineteen cancer patients at 32 sites completed the study. Most patients were female (81%); of this group, 69% had breast carcinoma. A highly statistically significant linear trend demonstrating improved response with higher doses was detected for complete response (no emetic episodes and no rescue medication) (P < 0.001), for complete plus major response (0-2 emetic episodes and no rescue medication) (P < 0.001), and for patient visual analog scale assessments of nausea (P = 0.001) and general satisfaction with antiemetic therapy (P = 0.001). No serious adverse events were noted. The most frequent adverse event was mild, self-limiting headache, which has been reported with other drugs in this class. CONCLUSIONS:
|
Authors | E B Rubenstein, R J Gralla, J D Hainsworth, P J Hesketh, T H Grote, M R Modiano, A Khojasteh, L A Kalman, C R Benedict, W F Hahne |
Journal | Cancer
(Cancer)
Vol. 79
Issue 6
Pg. 1216-24
(Mar 15 1997)
ISSN: 0008-543X [Print] United States |
PMID | 9070501
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Antiemetics
- Antineoplastic Agents
- Indoles
- Quinolizines
- Doxorubicin
- dolasetron
- Cyclophosphamide
|
Topics |
- Administration, Oral
- Antiemetics
(administration & dosage, adverse effects)
- Antineoplastic Agents
(adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Cyclophosphamide
(adverse effects)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Doxorubicin
(adverse effects)
- Female
- Humans
- Indoles
(administration & dosage, adverse effects)
- Male
- Middle Aged
- Nausea
(chemically induced, prevention & control)
- Quinolizines
(administration & dosage, adverse effects)
|